Combining Rb2 gene with radiation therapy quickens tumor cell death, Temple researchers find
Combining the tumor suppressing Rb2 gene with doses of gamma radiation speeds up the ability of tumor cells to die, according to a study by researchers at Temple Universitys College of Science and Technology.
Photo Credit: Joseph V. Labolito
Antonio Giordano, M.D., Ph.D., an internationally recognized researcher in the genetics of cancer and gene therapy, joined the faculty of Temple Universitys College of Science and Technology (CST) on March
The results of the study, "pRb2/p130 promotes radiation-induced death in glioblastoma cell line HJC12 by p73 upregulation and Bcl-2 downregulation," appear in the August 29 issue of Oncogene (Vol. 21, Issue 38).
In the study, which was started at Thomas Jefferson University and completed at Temples Sbarro Institute for Cancer Research and Molecular Medicine, the researchers found that when they treated tumor cells in which the Rb2 gene has been transplanted with gamma radiation, there was an increase of almost 50 percent in the ability of the cells to destroy themselves.
"One of the characteristics of the tumor cells is, at a certain point, the ability of the cell to program its own death, which is called apoptosis," says Antonio Giordano, Ph.D., M.D., head of the Sbarro Institute and one of the studys lead researchers. "In this case, we wanted to know if the introduction of the Rb2 gene into the tumor cell was creating apoptosis."
Giordano says that in order to kill tumor cells through apoptosis, the cells can be treated with gamma radiation, but that this therapy doesnt always have the desired effect.
In their study, the researchers transplanted a correct copy of the Rb2 into an aggressive brain tumor known as a glioblastoma using a vector that is sensitive to the drug tetracycline.
"When you have the presence of tetracycline, the Rb2 gene is in a silent state," says Giordano. "When you remove the tetracycline, you enhance the Rb2 gene expression and the tumor cells die.
As part of the study, the researchers treated the tumor cells in which they had transplanted the Rb2 gene with gamma radiation. "When we looked at the possible synergistic role between gamma radiation and the Rb2 gene therapy, we saw that when we combine enhanced Rb2 expression with the gamma radiation treatment, there was an increase of almost 50 percent in the ability of the cells to die from apoptosis," says Giordano, a professor of biology at Temple (http://www.temple.edu/news_media/hkg696.html), who discovered the Rb2 gene while working as a researcher at Temples Fels Institute for Cancer Research and Molecular Biology in the early 1990s. "So the gamma radiation at this point really helped in promoting quicker cell death in the cancer cells when it was combined with gene therapy."
Giordano adds that the researchers concluded that the Rb2 introduction into gamma radiation-induced cells was also associated with the up- and down-regulation of other molecules involved in apoptosis, namely Bcl-2, an anti-apoptic factor, and p73, a tumor suppressor related to the p53.
"Rb2/130 at this point is known to inhibit tumor progression by interfering with the cell cycle and, as previously demonstrated, is involved in angiogenesis," says Giordano. "But at this point, it is also able to control another important process in cancer and thats apoptosis.
"With all of the data weve produced so far, clearly, weve built another step in demonstrating that Rb2/p130 indeed is a guardian of the genome and able to participate in all key normal cell processes," he adds, "and therefore, it is becoming an essential target both for diagnosis and therapy."
The study, which was led by Giordano and Dr. Pier Paolo Claudio, associate professor of biology at Temple and a member of the Sbarro Institute, was an international collaborative effort, and included the Sbarro Institute, Temples Center for Neurovirology and Cancer Biology, Thomas Jefferson University, the University of Naples and the University of Rome in Italy. The National Institutes of Health and the Sbarro Health Research Organization funded the research.
Preston M. Moretz | EurekAlert!